Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $151M
Founded date: 2018
Investors 6
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
| - | Omega Fund... | omegafunds... |
| - | RA Capital... | racap.com |
| - | WRF Capita... | wrfseattle... |
| - | Adams Stre... | adamsstree... |
| - | Sahsen Ven... | sahsen.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.04.2021 | Series B | $100M | - |
| 03.10.2019 | Series A | $51M | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 25.04.2024 | 1st Quarter Results | 1st Quarter Results Thu, Apr 25, 2024 08:00 CET Report this content AstraZeneca 25 April 2024 Q1 202... | news.cisio... |
| 08.04.2024 | Clover Announces Positive Preliminary Phase I Results for Bi... | -- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,... | en.prnasia... |
| 19.02.2024 | AstraZeneca completes acquisition of Icosavax | AstraZeneca completes acquisition of Icosavax Mon, Feb 19, 2024 16:20 CET Report this content 19 Feb... | news.cisio... |
| 12.12.2023 | AstraZeneca to acquire Icosavax | AstraZeneca to acquire Icosavax Tue, Dec 12, 2023 08:05 CET Report this content News Release Regulat... | news.cisio... |
| 22.05.2023 | Icosavax Announces $67.8 Million Registered Direct Offering ... | - | globenewsw... |
| 22.05.2023 | Icosavax Announces $67.8 Million Registered Direct Offering ... | - | tcgcrossov... |
| 01.08.2021 | Icosavax’s $182M IPO haul is key for RSV, but eyes are on it... | The field of companies pursuing a vaccine for respiratory syncytial virus (RSV) includes several pha... | medcitynew... |
| 07.07.2021 | Seattle-based Icosavax, which is developing COVID-19 vaccine... | Icosavax creates virus-like particles with technology licensed from the University of Washington’s I... | geekwire.c... |
| 07.04.2021 | Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine... | Icosavax creates virus-like particles with technology licensed from the University of Washington’s I... | geekwire.c... |
| 07.04.2021 | Icosavax lands $100M to take its virus-like particle vaccine... | The Seattle-based biotech is developing vaccines based on virus-like particles (VLPs), proteins that... | medcitynew... |
Show more